X-37 is a pharmaceutical discovery and development company, which uses advanced artificial intelligence technology from Atomwise, Inc. to discover novel drug candidates by screening vast libraries of chemical compounds against high-value pharmaceutical targets.

X-37

David Collier

CEO at Velocity Pharmaceutical Development

Kiersten Stead

Vice President at Edmonton Ultimate Legacy Committee

X-37 has closed a $14.5 million Series A financing, led by DCVC Bio and joined by Alpha Intelligence Capital and Hemi Ventures. X-37 was cofounded by AtomWise and an experienced team of pharmaceutical developers from Velocity Pharmaceutical Development. With AtomWise’s top #AI platform, we have alre... Read more

Software Companies

Artificial Intelligence Companies

Abraham Heifets

DCVC Bio

VC fund for computational biology startups

Alpha Intelligence Capital

Hemi Ventures

San Francisco

Consolidated city and county in California, United States

United States of America

Country primarily located in North America

San Francisco Bay Area

Metropolitan area in California, United States

California

Software Publishers

Publishing Industries

Information

Custom Computer Programming Services

Computer Systems Design and Related Services

Professional, Scientific, and Technical Services

Publishing Industries (except Internet)

Prepackaged Software

Computer Programming, Data Processing, And Other Computer Related

Business Services

Computer Programming Services

Pharmaceutical discovery and development company

X-37 Funding & Investors

Total Amount Raised: $14,500,000

X-37 Funding Rounds

Series A Investors

💸 Investors

📚 Popular Blog Posts